RESECTED LYMPH NODES AND SURVIVAL OF PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: AN OBSERVATIONAL STUDY

Increasing the Number of Resected Lymph Nodes Improves Overall Survival of Patients With Esophageal Squamous Cell Carcinoma With Positive Lymph Nodes: a Retrospective Analysis of 1656 Cases at a Single Cancer Center

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05570487

Enrollment

1600

Registered

2022-10-06

Start date

2022-10-01

Completion date

2023-10-01

Last updated

2022-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the Records of Esophageal Cancer

Keywords

esophageal cancer, lympha nodes

Brief summary

To clarify the effect of the number of lymph node dissection and the number of stations on survival

Interventions

DIAGNOSTIC_TESTSince the data were collected retrospectively, there were no interventions

Since the data were collected retrospectively, there were no interventions

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

1. Men and women aged 18-85; 2. Histologically confirmed primary thoracic esophageal squamous cell carcinoma, 3. Staging PT1-4A, N0-3, M0 AJCC eighth edition; 4. Excluding lymph node dissection \< 15,(meeting the guideline criteria)

Exclusion criteria

1. Patients with a history of previous thoracic and abdominal surgery that may affect lymphatic reflux 2. Patients with distant metastasis confirmed by imaging; 3. Patients with obvious surgical contraindications.

Design outcomes

Primary

Measure	Time frame	Description
The number of lymph nodes	2010.1.1-2017.12.30	Surgical data were retrospectively collected

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026